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Abstract
Background: Burden of Disease (BoD) studies use disability-adjusted life years (DALYs) as a population health
metric to quantify the years of life lost due to morbidity and premature mortality for diseases, injuries and risk
factors occurring in a region or a country. Small countries usually face a number of challenges to conduct
epidemiological studies, such as national BoD studies, due to the lack of specific expertise and resources or absence
of adequate data. Considering Europe’s small countries of Cyprus, Iceland, Luxembourg, Malta and Montenegro, the
aim was to assess whether the various national data sources identified are appropriate to perform national BoD
studies.
Main body: The five small countries have a well-established mortality registers following the ICD10 classification,
which makes calculation of years of life lost (YLL) feasible. A number of health information data sources were
identified in each country, which can provide prevalence data for the calculation of years lived with disability (YLD)
for various conditions. These sources include disease-specific registers, hospital discharge data, primary health care
data and epidemiological studies, provided by different organisations such as health directorates, institutes of
public health, statistical offices and other bodies. Hence, DALYs can be estimated at a national level through the
combination of the YLL and YLD information.
On the other hand, small countries face unique challenges such as difficulty to ensure sample representativeness,
variations in prevalence estimates especially for rarer diseases, existence of a substantial proportion of non-residents
affiliated to healthcare systems and potential exclusion from some European or international initiatives.
Recently established BoD networks may provide a platform for small countries to share experiences, expertise, and
engage with countries and institutions that have long-standing experience with BoD assessment.
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Conclusion: Apart from mortality registries, adequate health data sources, notably for cancer, are potentially available
at the small states to perform national BoD studies. Investing in sharing expert knowledge through engagement of
researchers in BoD networks can enable the conduct of country specific BoD studies and the establishment of more
accurate DALYs estimates. Such estimates can enable local policymakers to reflect on the relative burden of the
different conditions that are contributing to morbidity and mortality at a country level.
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Background
Burden of Disease (BoD) studies calculate disability-adjusted
life years (DALYs) to quantify the health of a population
through a single metric. DALYs are calculated through the
combination of ‘years lived with disability (YLD)’ and ‘years
of life lost (YLL)’ [1]. The YLD calculation relies on preva-
lence data. As part of the YLD calculation, disability weights
(DWs) are required. The DWs depend on the population
perception of living with a particular condition for a period
of a year. Disability weights ranges from 0, equivalent to opti-
mal health, to 1, equivalent to death. These DWs tend to
have a high level of agreement across different populations
for the majority of the conditions. Therefore, small countries
may consider using the already established DWs by the GBD
study [2]. Using DWs enable us to compare between a year
lost to death and a year spent with a specific disease, injury
or risk factor [1]. YLDs furthermore require severity distribu-
tions of conditions (e.g. mild/moderate/severe), which, in
contrast to DWs, cannot be considered to be identical across
countries. Indeed, it was reported that consideration for the
development of country specific severity distributions is mer-
ited [3]. However, considering the scarce resources, such an
exercise would be challenging, especially for small countries.
BoD estimates provide the foundations for planning and
prioritizing health policies at a population level, as well as
evaluating the effectiveness of interventions. Hence, it is es-
sential that such metric is regional- or country-specific. The
Global Burden of Disease (GBD) study provides estimates of
BoD for regions and countries across the world and is based
on a comprehensive methodology of complex statistical
models and specific assumptions [4]. However, concerns
have been raised about the methodology and the accuracy of
the severity distributions used in the GBD study, with the
recommendation to develop estimates on country-specific
data [3, 5]. The aim of this manuscript was to explore
whether small countries have conducted national BoD stud-
ies and whether their available data sources are appropriate
for conducting country-specific BoD studies.
Europe’s small countries
The small countries considered in this work are Cyprus,
Iceland, Luxembourg, Malta and Montenegro, all of
which are participating members of the COST Action
“European burden of disease network” [6]. The GBD
2019 study provides BoD estimates for these countries.
However the data sources used for these estimations are
not all locally-based studies or sources [2].
Availability of data sources
Mortality data
All considered European small countries have a central
ICD10-based mortality registry or database managed by the
Directorate of Health or Public Health authorities of the re-
spective country. Death certificates are filled in by trained
doctors and each certificate is inputted by a trained coder. In
some countries, such as in Iceland, death certificates allow
for multiple causes of death and hence multiple ICD10 codes
are required. In this case, the inputting of the death certifi-
cate is reviewed by a second trained coder, a doctor, to en-
sure the entrance of adequate and reliable ICD-10 codes.
Similarly, in Luxembourg, more than one coder is respon-
sible for inputting death certificates. This typically occurs
when technical issues are flagged on inputting such as un-
readable handwriting, handling missing data and in the case
of an external cause of death. This process is followed to
ascertain reliability in the inputting of the death certificate
within the registry. Although, such inputting strategy will
limit ill-defined causes of deaths (IDD). However,
Montenegro face challenges with IDD due to their recent
shift in the responsible authorities for the mortality database
system, therefore, the registry is currently not yet fully func-
tional. Hence, calculation of YLLs following the GBD meth-
odology [7] is feasible, but the accuracy of the estimation is
country-dependent.
Morbidity data
A number of health information data sources can be
used to monitor the prevalence and severity distributions
of diseases, injuries or risk factors. The feasibility to use
the already published national data as a source to calcu-
late the YLD is dependent on the country’s population
coverage and quality of data. It is also dependent on a
whether these national data sources provide information
on disease prevalence and its severity.
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Health information sources
Overall, each small country has an entity that records
health information at the population level, such as a
Health Directorate, an Institute of Public Health or Stat-
istical Office. Such health information system is repre-
sentative of the population and suitable for estimating
prevalence of diseases, risk and injuries. A question lies
as to the ease of accessibility to all the data and the inte-
gration of such data for YLDs calculation, especially
since severity of the condition may not be readily avail-
able from a single data source and would depend on
other sources. In the digital health era, linking data may
be feasible if a common identifiable code/number is
assigned to each patient, enabling cross-linkage of data
across the data platforms. Researchers can use such data
sources provided that appropriate permissions were
gathered before or during data collection to allow for
anonymised data linkage and use. This requires the pres-
ence of secured health information infrastructure, which
may not be available, especially in small countries. Small
countries typically have limited resources and are more
likely to invest in the set-up of healthcare service infra-
structure rather than the collection and linking of health
information data [8].
Primary health care (PHC) data can also provide in-
valuable information. In Montenegro, the PHC data has
been integrated with the Institute of Public Health data-
base with the goal to enable analysis for research pur-
poses. Such a data linkage may provide an adequate data
source for BoD studies. However, not all small countries
can access such data freely, whilst others may be faced
with a methodological challenge of establishing sample
representativeness of the population using such data. In
Malta, although the PHC is state run and free for all tax-
paying residents, only a proportion of the population
seek medical advice and care at PHC. The majority of
the population opts to visit private general practitioners
that do not have a common data sharing platform, mak-
ing this data source unreliable for BoD studies.
Disease-specific registries
The availability of different registries among the different
small countries might help to estimate the prevalence
data required for certain conditions. Table 1 gives a
comparative summary of the registries available for each
small country. A number of different disease registries
are available within these small countries. The common
ones are cancer registries.
In Malta, different registries are being kept by different
entities. An example is the population free medicine pre-
scription registry for chronic diseases. This is kept by
the ‘Pharmacy of Your Choice (POYC)’ unit which falls
under the umbrella of the Ministry for Health, whilst the
cancer registry is kept by the Directorate of Health In-
formation and Research. A similar scenario is present in
Luxembourg, where different entities are responsible for
the management of different registries. This is a clear ex-
ample of fragmentation of data sources. Using disease-
specific registries as a source for YLDs calculations
comes with advantages and disadvantages. An advantage
Table 1 Comparative summary of the different disease-specific registers available in the different small European member states
Morbidity registry Cyprus Iceland Luxembourg Malta Montenegro
Cancer Yes Yes Yes Yes Yes
HIV/AIDS Yes No Yes No No
Communicable diseases No Yes Yes No Yes
Diabetes Yes No No No Yes
Cardiovascular disease No Yes No No Yes
Nosocomial infections No No Yes No No
Perinatal health No No Yes No No
Rare diseases No No No Yes No
Cerebral palsy No No No Yes No
Birth defects No No No Yes No
Dementia No No No Yes No
Hospital discharge/statistics No Yes Yes Yes No
Prescription medicines No Yes No Yes No
Drug and drugs addiction No No Yes No YEs
Trauma and accident No Yes Yes No No
Vaccination No Yes No Yes Yes
Transplants No No No Yes No
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is that medical professionals are usually responsible for
the reporting of cases using standardised protocols
which are then recorded within the registers. This data
source may also be appropriate for disease severity dis-
tribution estimations. Compared to data available from
epidemiological studies, such registers, may not include
all patients falling within the register’s category, due to
discrepancies in the categorisation of patients occurring
from interpersonal bias. This may also result in missing
out patients, as individuals with a particular disease, may
be opting out of visiting the healthcare system and
hence may not be registered within the database. Such
population representation of the data source is
dependent on the country population attitudes and be-
haviours with respect to the use of healthcare services.
Hospital discharge data
Hospital discharge data is another potential source that
can be used by small countries for BoD studies, which
provides information on prevalence and severity distribu-
tion of diseases. Of note, this kind of data will only be able
to account for the upper end of the disease’s severity scale
that require admission. This may have an effect on the
prevalence estimations of certain diseases and injuries.
Hospital discharge data is available across all the pub-
lic hospitals of the small countries under study, although
accessibility and quality of this data differs by country.
For example, in Malta, the digital hospital discharge data
is only available from the year 2007 onwards. Discharge
data documentation is the responsibility of the ward
doctor and details provided as part of this report is sub-
ject to the ward doctor’s writing preference.
An additional issue in utilization of hospital discharge
data is the degree of population data representation.
This is especially true for the countries that have a num-
ber of public and private hospitals. The reliability of hos-
pital discharge data will hence vary between countries.
For example, in Iceland where there are only public hos-
pitals, hospital discharge data may be a reliable morbid-
ity data source for BoD studies. Montenegro also has
only public hospitals, therefore, hospital discharge data
are nationally representative. However, tracking data by
patient imposes an issue, as data are mostly available in
an aggregated form. In countries where a mixture of
public and private hospitals is present (such as in Malta),
using hospital discharge data provided by public hospi-
tals may not be a representative yield of the whole coun-
try. The case for Cyprus is different as it has recently
undergone the implementation of a general health sys-
tem serving as the aegis for the direct competition of
public and private hospital in universal coverage
provision [9]. The responsible unit for such data remains
the Monitoring Health Unit (MHU). Similarly, in
Luxembourg, a new hospital documentation system
(www.dcsh.lu) is being set up that combines the medical
documentation of all public and private hospitals to-
gether through diagnosis-related groups (DRG) using
two classifications for diagnosis (ICD-10 CM) and for
procedures (ICD-10 PCS).
Health insurance data
Private health insurance is not obligatory for the popula-
tion of these small countries since health care is pro-
vided as part of the National Health Insurance.
Therefore, using private health insurance data may not
be representative of the small country’s characteristics
and should not be considered as the primary morbidity
data source.
Epidemiological studies
A number of epidemiological studies have been con-
ducted in these small countries. These studies fall within
the frame of the ‘European Health Interview Surveys
(EHIS)’, which follow the European Commission Regula-
tion for health statistics. The corresponding datasets are
easily accessible through Eurostat and provide informa-
tion on the health status, health care use, health deter-
minants and socio-economic background of each
country (https://ec.europa.eu/eurostat/data/database). A
number of other nationally representative surveys have
been carried out in Iceland, Luxembourg, Malta and
Montenegro, focusing on different aspects of health in
adults and in children including specific age groups
(such as the Health Behaviour in School-age Children –
HBSC) and others focused on non-communicable dis-
ease risk factors (tobacco use and alcohol consumption,
obesity). Surveys conducted in small countries are typic-
ally representative of the population and may also be a
good source for estimating prevalence and disease spe-
cific severity distribution. The challenge however re-
mains whether data from such sources can be used to
draw comparisons between countries, since these sur-
veys (especially health examination surveys) are not run
on a standardized basis.
Feasibility and challenges for national burden of disease
study in small countries
The small population size may constitute an advantage for
the collection of health information; however, these coun-
tries are also faced with challenges arising from the lack of
resources and expertise in certain areas. Among other bar-
riers, small countries have distinctive challenges related to
limited accessibility to health data and information, ham-
pering them from performing national BoD studies.
To date, the small countries in question have not con-
ducted national BoD studies. A number of different
health information sources are readily available in each
of the small countries that can provide prevalence-based
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data for calculation of YLDs and mortality data for cal-
culation of YLLs, both of which are required to perform
national BoD studies. However, most health data sources
are typically fragmented with routine country health sta-
tistics and epidemiological studies being conducted sep-
arately and kept by different entities. The concern about
data fragmentation is that data linking may not always
be possible even in small countries, such as data gath-
ered by the state cannot be linked to data gathered by
private entities such as insurance companies or general
practitioners. Of note, absence of standardization of data
capturing and storage among small countries could be
clearly observed in Table 1. A difference in the type of
disease and injuries registries was evident, which may
hinder countries in conducting comparative BoD studies.
These issues may be originating from scarce resources
that affects the set-up of health data infrastructure. Fur-
thermore, some small countries may face legal and tech-
nical constraints against unique data codification and
linkage from different sources, which will make data ac-
cessibility problematic. Additionally, using multiple
sources to calculate YLD may be subject to overesti-
mation of the condition’s impact even more so if multi-
morbidity is present. Hence, it is essential that data
triangulation is performed by following a data linkage
process through a unique identifiable number (if avail-
able) to ensure a creditable of the data source.
Achieving a survey/study’s population sample represen-
tation is another challenge faced by small countries. A
representative survey depends on the number of re-
sponders. Small countries require a greater proportion of
the population to be sampled and to participate to main-
tain population representation than larger countries [8].
Also, the per capita cost of a survey tends to be larger to
run in a small country than a larger one [8]. Hence, con-
sidering these challenges along with the fact that small
countries have typically limited resources and low partici-
pation rates (as experienced by other countries), sample
study representation may be a significant issue.
The use of secondary data can lead to inaccuracies such as
overestimation of the DALYs, which can be avoided by con-
ducting full BoD studies of the different conditions that affect
each country [10]. It is recommended, as a first step, to
undergo a pilot BoD study to ensure that the methodology
and the outcomes are reliable and comparable to other coun-
tries. Indeed, a harmonized methodology is a requisite along
with performing of standardization by measuring BoD rates
per 100,000 population. However, this requires a vast num-
ber of resources and expertise, which are considered as very
limited in these small countries. In addition, the concept of
BoD may not have been recognised as an essential tool for
policymaking in small countries. Hence, this may present an
additional hurdle in financing and supporting the conduct of
national BoD studies.
Small countries face specific challenges such as the
presence of a very small number of cases and/or deaths
for a particular condition or rare diseases. This may in-
fluence the prevalence estimates in contrast to larger
countries where the estimated prevalence would not
drastically change with the addition of new diagnosed
cases. In order to avoid potential skewing of the results,
these cases may require the grouping of conditions into
broader categories, which will have an effect on the ac-
curacy of YLD’s and YLL’s measurements. This may give
an inaccurate picture of the BoD for small countries.
Another challenge faced by some small countries comes
from the relatively large proportion of non-residents within
the country. An example is Luxembourg, where a number of
‘cross-border’ employees who work in the country are affili-
ated with the national health security system. Therefore,
using such data to estimate the YLDs would over/under-rep-
resent the BoD. In Iceland and in Malta a proportion of the
residents do not hold an Icelandic or Maltese citizenship,
however, are eligible for social and health services since they
originate from the European Economic Area (provided they
have been residents for 6 months). Hence, the morbidity data
available will incorporate national citizens and immigrant
population, which again will have an effect on the DALYs. In
theory this could be addressed by performing BoD studies
stratified by nationality; however, information on nationality
is not available in all health data sources, preventing such an
approach. Finally, some small countries (e.g. Iceland and
Montenegro), that are not part of the European Union (EU),
may not be eligible to participate in certain European or
international initiatives.
The way forward
As the BoD concept gains prominence, an increasing
number of countries are exploring the possibility to con-
duct national BoD studies. In this respect, small states
are confronted with a number of challenges – some
common to all countries, some very specific to the small
size of the population and the public health sector. To
help address these challenges, recently established BoD
networks may provide a platform for small countries to
share experiences and expertise with each other, and to
engage with other countries and institutions that have
long-standing experience with BoD assessment [6].
Through these networks, small countries may further
develop their capacity in BoD assessment and find op-
portunities for jointly addressing the challenges they and
other countries are faced with.
Conclusions
Small European member states have adequate data
sources that can be used for national BoD studies. How-
ever, better co-ordination between departments is
needed, as well as the use of international BoD expertise
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and resources. Therefore, it is considered that investing
in such expertise can yield more accurate DALYs esti-
mates. Such estimations can enable the local policy-
makers to identify the population needs more accurately,
as well as reflect on the relative burden of the different
conditions that are contributing to morbidity and mor-
tality at a country level. Establishing data sources and
supporting the conduct of BoD studies can contribute to
better research and policymaking in these small states.
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